RDHL — Redhill Biopharma Share News
0.000.00%
Last trade - 00:00- $3.76m
- -$0.32m
- $0.29m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM
NASDAQ RESUMED AT 09:00 AM
Brief: Redhill Divests Talicia To Apotex For $18 Million Cash Upfront Plus Milestones
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:57 AM
Brief: Redhill Biopharma Announces Closing Of Up To $19.4 Million Private Placement
Brief: Redhill Biopharma Announces Up To $19.4 Million Private Placement
Brief: Redhill's Opaganib Receives FDA Rare Pediatric Disease Designation For Neuroblastoma In Addition To Current Orphan Drug Designation
Brief: Redhill Biopharma - Commences Enforcement Of $10.9 Million New York Judgment Against Kukbo In Korea
Brief: Redhill Biopharma Advances Opaganib Options For Ebola Virus Disease Outbreak
Brief: RedHill Biopharma - Actively Discussing Potential Collaborations For Advancement Of Its Investigational Oral Drug, Opaganib
Brief: Redhill Biopharma Files Prospectus Related To Offer And Sale Of ADSS By Selling Shareholder
Brief: RedHill Biopharma - On Dec 19, Co Entered Into Standby Equity Purchase Agreement With Ya Ii Pn
Brief: Redhill Biopharma's Positive Opaganib Results Indicate Reduction In Venetoclax Resistant Cells
Brief: Redhill Biopharma Successfully Regains Compliance With Nasdaq Stockholders' Equity Requirement
Brief: RedHill Announces $10.5 Mln NY SC Judgment Win Now Final For Enforcement
Brief: Redhill Biopharma Receives Nasdaq Staff Determination Notification
Brief: CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO